ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ocrelizumab

Also written as “Ocrelizumab”, “CYB704” and “OCR SC”.

Its studies are mostly in Multiple Sclerosis · Arthritis, Rheumatoid · Multiple Sclerosis, Chronic Progressive · Multiple Sclerosis, Relapsing-Remitting · Lupus Nephritis, led by 5 companies.

Drug pageOcrelizumab: every studyMany companies study it; this page follows only the 42 they lead. All 56 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 5, 201842 company-led studies, 13 open or runningNext primary completion: Feb 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only3810 open or runningphase 4since Jul 5, 2018Feb 12, 2004Dec 31, 2027phase 3 · NCT05269004
Celltrionits history only11 open or runningphase 3since May 9, 2023May 9, 2023Feb 2027phase 3 · NCT05906992
Cinnagen10 open or runningphase 3since Jun 27, 2021Jun 27, 2021none ahead
R-Pharmits history only11 open or runningphase 1since Apr 13, 2026Apr 13, 2026none ahead
Sandozits history only11 open or runningphase 3since Feb 19, 2025Feb 19, 2025none ahead

Also a collaborator on its studies: PPD Development, LP, Laboratory Corporation of America and Roche Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Cinnagen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 27, 2021First study: phase 3 study in Multiple SclerosisFirst studyNCT04966338 · 170 enrolled · Iran, Islamic Republic of

TargetBeta

MS4A1 →read by rule
“A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
RituximabruleHoffmann-La Rochephase 4175
obinutuzumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

The one study Cinnagen leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04966338Multiple Sclerosis · Iran, Islamic Republic of3CompletedNov 9, 2020170

How it is read

Names in the registry

  • “Ocrelizumab”, 36 entries
  • “ocrelizumab”, 2 entries
  • “CYB704”, 1 entry
  • “OCR SC”, 1 entry
  • “Ocrelizumab SC”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.